Tetraphase to present data on next-generation antibiotics portfolio

theflyonthewall.com

Tetraphase Pharmaceuticals announced that it will present at the Interscience Conference on Antimicrobial Agents and Chemotherapy the results of important research that supports the potential of the company’s next-generation antibiotics portfolio, including its lead candidate eravacycline in the treatment of difficult-to-treat bacterial infections. Data to be presented will highlight dosing of eravacycline in the company’s phase 2 clinical trial in complicated intra-abdominal infections as well as its activity in preclinical studies against neisseria gonorrhoeae, a common but increasingly resistant cause of gonococcal disease. Tetraphase recently dosed the first patient in its phase 3 clinical trial in cIAI. This marks the first of two planned phase 3 clinical trials. One in complicated intra-abdominal infections and one in complicated urinary tract infections that the company plans to initiate later this year. Data will also be shared on preclinical antibiotic candidate TP-271’s ability to combat the effects of aerosolized biological weapons, specifically the highly virulent pathogen francisella tularensis.

Rates

View Comments (0)